Please login to the form below

Not currently logged in

Novartis invests $1.3bn in protein degradation technology

Novartis will work with UK-based start-up Dunad Therapeutics to develop protein degradation drugs

Novartis has signed a strategic collaboration with UK-based start-up Dunad Therapeutics to develop next-generation therapies harnessing the company’s protein degrader technology.

Protein degrader therapies use the body’s own ability to break down proteins to remove rogue molecules associated with disease from cells. The platform developed by Dunad is 'tunable and highly selective', using small molecules to 'induce selective degradation' of disease-causing and often undruggable proteins through direct modification of the target.

“To date, there has not been a broadly applicable, plug-and-play, monovalent approach to protein degradation, and we believe Dunad’s unique platform provides the potential to deliver next-generation degrader therapeutics with advantages over traditional drugs against a wide range of diseases,” said Dunad co-founder and chief scientific officer, Professor Patrick Gunning.

The deal – which gives Novartis exclusive option to license, develop and commercialise candidates for up to four targets – sees Dunad receive $24m in an upfront payment and equity investment as well as research funding. After that, it will receive up to $1.3bn in discovery, development, regulatory and sales-based milestones, as well as royalty payments.

Novartis will be responsible for future development, manufacturing and global commercialisation of the small molecule therapeutic products generated against the agreed targets​.

Dunad, which was only founded last year, is backed by founding investor Epidarex Capital as well as BioGeneration Ventures.

The deal is not the first to focus on protein degradation technology; in fact, there have been two major deals in the past few months. In late summer, Eli Lilly signed a $1.6bn deal with Lycia Therapeutics for up to five drug targets using its lysosomal targeting chimera (LYTAC) protein degradation technology. Lycia’s tech was developed by co-founder Professor Carolyn Bertozzi from Stanford University and has an initial focus on projects in immunological disease and pain.

In July, Pfizer paid $1bn upfront to Arvinas (plus an additional $1.4bn in future milestone payments and a share of profits) for ARV-471, a breast cancer candidate currently in phase 2 trials but expected to enter phase 3 next year.

Article by
Hugh Gosling

3rd November 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
Serious about sustainability?
Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...
How scientific storytelling can help Pharma cut through the noise
Rather than being afraid of storytelling, pharmaceutical firms should be embracing it. Because what scientific storytelling allows us to do is to communicate quickly and efficiently. It provides a shortcut...